Northern Trust
NGNE icon

Northern Trust’s Neurogene NGNE Stock Holding History

Northern Trust’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Buy
97,621
+12,062
+14% +$234K ﹤0.01% 2985
2025
Q4 		$1.76M Sell
85,559
-4,539
-5% -$113K ﹤0.01% 3076
2025
Q3 		$1.56M Sell
90,098
-3,073
-3% -$61.7K ﹤0.01% 3170
2025
Q2 		$1.39M Sell
93,171
-17,239
-16% -$271K ﹤0.01% 3205
2025
Q1 		$1.29M Buy
110,410
+9,844
+10% +$171K ﹤0.01% 3162
2024
Q4 		$2.3M Buy
100,566
+5,845
+6% +$218K ﹤0.01% 2944
2024
Q3 		$3.97M Buy
94,721
+65,982
+230% +$2.56M ﹤0.01% 2611
2024
Q2 		$1.05M Buy
28,739
+6,104
+27% +$215K ﹤0.01% 3231
2024
Q1 		$1.15M Buy
+22,635
New +$756K ﹤0.01% 3250
2023
Q4 		– Sell
-3,432
Closed -$54.2K – 4517
2023
Q3 		$54.2K Sell
3,432
-45
-1% -$664 ﹤0.01% 4148
2023
Q2 		$57.7K Sell
3,477
-11
-0.3% -$180 ﹤0.01% 4187
2023
Q1 		$48.8K Hold
3,488
– – ﹤0.01% 4276
2022
Q4 		$35.5K Hold
3,488
– – ﹤0.01% 4366
2022
Q3 		$45K Sell
3,488
-7
-0.2% -$143 ﹤0.01% 4349
2022
Q2 		$72K Sell
3,495
-11,947
-77% -$291K ﹤0.01% 4293
2022
Q1 		$581K Sell
15,442
-883
-5% -$51.5K ﹤0.01% 3678
2021
Q4 		$1.57M Sell
16,325
-1,244
-7% -$152K ﹤0.01% 3340
2021
Q3 		$2.54M Sell
17,569
-656
-4% -$100K ﹤0.01% 3148
2021
Q2 		$3.36M Sell
18,225
-473
-3% -$105K ﹤0.01% 3078
2021
Q1 		$4.6M Sell
18,698
-1,563
-8% -$399K ﹤0.01% 2804
2020
Q4 		$5.71M Sell
20,261
-564
-3% -$138K ﹤0.01% 2601
2020
Q3 		$5M Buy
20,825
+13,821
+197% +$3.35M ﹤0.01% 2532
2020
Q2 		$2.33M Buy
7,004
+3,232
+86% +$842K ﹤0.01% 2960
2020
Q1 		$859K Buy
3,772
+1,034
+38% +$213K ﹤0.01% 3280
2019
Q4 		$675K Buy
2,738
+411
+18% +$40.9K ﹤0.01% 3500
2019
Q3 		$133K Sell
2,327
-357
-13% -$21.8K ﹤0.01% 3860
2019
Q2 		$127K Sell
2,684
-93
-3% -$4.78K ﹤0.01% 3922
2019
Q1 		$149K Hold
2,777
– – ﹤0.01% 3832
2018
Q4 		$120K Sell
2,777
-1,645
-37% -$80.1K ﹤0.01% 3887
2018
Q3 		$259K Sell
4,422
-3
-0.1% -$177 ﹤0.01% 3796
2018
Q2 		$235K Sell
4,425
-14
-0.3% -$3.65K ﹤0.01% 3807
2018
Q1 		$1.25M Buy
4,439
+198
+5% +$54.7K ﹤0.01% 3307
2017
Q4 		$998K Sell
4,241
-21
-0.5% -$4.92K ﹤0.01% 3407
2017
Q3 		$1.21M Buy
4,262
+102
+2% +$29.3K ﹤0.01% 3392
2017
Q2 		$1.17M Buy
4,160
+134
+3% +$38.3K ﹤0.01% 3403
2017
Q1 		$1.34M Sell
4,026
-80
-2% -$28.1K ﹤0.01% 3248
2016
Q4 		$1.36M Buy
4,106
+904
+28% +$243K ﹤0.01% 3262
2016
Q3 		$856K Buy
3,202
+665
+26% +$134K ﹤0.01% 3386
2016
Q2 		$336K Buy
2,537
+1,865
+278% +$296K ﹤0.01% 3595
2016
Q1 		$118K Hold
672
– – ﹤0.01% 3869
2015
Q4 		$168K Hold
672
– – ﹤0.01% 3816
2015
Q3 		$189K Buy
+672
New +$155K ﹤0.01% 3768

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Northern Trust's NGNE Position: Q1 2026 in Review

Northern Trust increased its Neurogene (NGNE) stake by 14% in Q1 2026, buying an estimated $234K and bringing the position to 97,621 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

Northern Trust first reported a position in NGNE in Q3 2015 and has held it in 42 quarters since. The position peaked at $5.71M in Q4 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Northern Trust held 97,621 shares of Neurogene worth $1.97M as of Q1 2026.
  • Northern Trust bought 12,062 Neurogene shares in Q1 2026, an estimated $234K.
  • Neurogene made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2985 holding.
  • Northern Trust first reported a position in Neurogene in Q3 2015 and has held it in 42 quarters since.
  • Northern Trust's Neurogene position peaked at $5.71M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.